New RSV vaccine trial aims to shield seniors from severe lung infections
NCT ID NCT07128121
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests a new mRNA vaccine called IN006 to protect against respiratory syncytial virus (RSV) in healthy adults aged 60 and older. About 500 participants will receive either the vaccine or a placebo, and researchers will monitor side effects and immune responses for up to 2 years. The goal is to find a safe and effective dose that can prevent serious RSV illness in older adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China
Conditions
Explore the condition pages connected to this study.